Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.
In the last post, I mentioned the Twitter response to the Brazilian rejection of the Gamaleya vaccine. I believe that the official blue-check-marked “Sputnik V” Twitter account is run by the Russian Direct Investment Fund, the sovereign-wealth part of the Russian state that is in charge of rolling out the vaccine to different countries. Read More
I mentioned yesterday in my post about anti-vaccine arguments that there seemed to be suspicions on social media platforms about vaccine testing in Africa. I’ve been looking around for more of that, and finding plenty of it. I’ve also heard from a colleague with some pertinent thoughts about how these things get going, and I… Read More
I had not been planning to return to the topic of hydroxychloroquine so soon, but here we are. This will not be a calm, measured blog post – fair warning. Yesterday, Dr. Rick Bright was pushed out of his post at HHS, where he was deputy assistant secretary for preparedness and response and director of BARDA… Read More
I suspect that most readers will have heard the news that Charles Lieber, nanoscale materials chemist and chair of Harvard’s chemistry department, was arrested yesterday by federal agents. He was accused of providing false statements to government agencies about his involvement with China’s “Thousand Talents” program and wit… Read More
Word came out yesterday from Frances Arnold of Caltech (via her Twitter account) that she and her co-authors are retracting this paper from Science. The retraction notice itself has the details: After publication of the Report “Site-selective enzymatic C‒H amidation for synthesis of diverse lactams” (1), efforts to reproduce the work showed t… Read More
This paper is right, and it says things that need to be said. I wonder, though, if saying them will do any good. Let me explain what the heck I’m talking about! The paper is titled “Blocking the Hype-Hypocrisy-Falsification-Fakery Pathway is Needed to Safeguard Science“, and I don’t see how anyone can really disagree. When… Read More
This is not going to be a reassuring story – not for the biomedical literature, and not for the Chinese scientific establishment. But the head of the official Research Integrity initiative there, Xuetao Cao, a former head of the Chinese Academy of Medical Sciences and current president of Nankai University, is now thoroughly involved in… Read More
The ways to mess around with the peer-review process are legion, but these schemes are getting a bit easier to catch. That’s what I take away from this paper, from two bibliographic scientists at Elsevier who set up a system to do just that. One hears tales of reviewers who will look more favorably on… Read More
It’s a summer Friday, so I’ll just send along this link to a story at Wired. It’s similar to this recent post, in that it details some of the ridiculous ways that small overseas manufacturers have tried to get around FDA site inspections. As a correspondent noted, though, the title of the Wired article isn’t… Read More
This article at Stat by Rebecca Robbins really caught me eye. It describes clinical trials where the participants are being asked to pay thousands of dollars just to join the trial. There seems to have been an increase in this sort of thing lately, and I’ll be completely clear: I think that’s a terrible idea… Read More
